FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medications and deals with application of miliacin as medication which increases antitumour effect of methotrexate.
EFFECT: extension of arsenal of medications, which increase antitumour effect of methotrexate.
3 dwg
| Title | Year | Author | Number | 
|---|---|---|---|
| METHOD OF PROTECTING POST-VACCINATION IMMUNITY TO TETANUS ANATOXIN AGAINST METHOTREXATE-INDUCED DEPRESSION | 2008 | 
 | RU2394577C1 | 
| TUMOUR THERAPY AGENT | 2019 | 
 | RU2726801C1 | 
| ANTIMUTAGENIC AGENT | 2019 | 
 | RU2698204C1 | 
| METHOD OF LUNG CANCER TREATMENT | 2008 | 
 | RU2365370C1 | 
| DERIVATIVE OF THE CLASS OF N-GLYCOSIDES INDOLO[2,3-A]PYRROLO[3,4-C]CARBAZOLE-5,7-DIONE - N-{12-(β-D-XYLOPYRANOSYL)-5,7-DIOXO-INDOLO[2,3-A]PYRROLO[3,4-C]CARBAZOL-6-YL} PYRIDINE-2-CARBOXAMIDE, WHICH HAS CYTOTOXIC AND ANTITUMOR ACTIVITY | 2017 | 
 | RU2667906C1 | 
| LUNG CANCER THERAPY | 2008 | 
 | RU2367436C1 | 
| ANTI-TUMOR NAPHTHOINDOLE-3-CARBOXAMIDE DERIVATIVE | 2019 | 
 | RU2712191C1 | 
| PHOSPHOLIPID COMPOSITION OF DOXORUBICIN FOR TREATING PATIENTS WITH BREAST CANCER | 2019 | 
 | RU2714137C1 | 
| ANTICANCER AGENT | 2014 | 
 | RU2575572C1 | 
| AGENT FOR INCREASING EFFICACY AND REDUCING TOXICITY OF ANTINEOPLASTIC PREPARATIONS | 2009 | 
 | RU2410095C2 | 
Authors
Dates
2011-02-20—Published
2009-06-09—Filed